DR. GAYATRI SABERWAL

My group researches the bio-pharma industry, both in India and abroad. Aside from studying the formation and nature of companies per se, we also analyze their patent holdings. We believe that such studies, both quantitatve and qualitative, will prove useful to policy making that is geared to supporting the industry.

In addition we have a series of general articles in Current Science entitled 'Bio-business in brief'. These articles highlight different aspects of industry, possibly of interest to academic researchers. We hope that they will contribute to the engagement of academia with industry, vital to producing a knowledge driven industry, itself important to ensure a healthier India.

RELEVANT RESEARCH PUBLICATIONS

Marimuthu, G., Kumari, S., Kandasamy, M., Raghunathan, S. and Saberwal, G.
Patents protecting biologics or small molecule drugs are usually maintained.
Nature Biotechnology, 30, 50-53 (2012)

Soby, S, Sebastian, T.E. and Saberwal, G.
US patent holdings of Indian non-corporate entities.
Asian Biotechnology Development Review (in press)

Sebastian, T.E., Pattnayak, J.P., Soby, S and Saberwal, G.
Patent holdings of Indian pharmaceutical and biotechnology companies in international markets of different sizes.
Asian Biotechnology Development Review, 13, 17-37 (2011)

Saberwal, G.
Seeding a skilled workforce.
Nature Biotechnology, 27, 773-775 (2009)

Sebastian, T.E., Chandra Bindu, Y. and Saberwal, G.
Patent holdings of US biotherapeutic companies in major markets.
Drug Discovery Today, 14, 442-445 (2009)

Sundaramoorthy, S., Chandra Bindu, Y. , Mehdiratta, R. and Saberwal, G.
The US patent holdings of homegrown Indian biotech and pharma companies.
Current Science, 96, 252-259 (2009)

Parida, D.K, Mehdiratta, R. and Saberwal, G.
How many patents does a bio-therapeutics company need?
Nature Biotechnology, 26, 763-766 (2008)

Saberwal, G
New pharma-biotech company formation in India
Nature  Biotechnology, 24, 499-501 (2006)

SERIES OF ARTICLES IN CURRENT SCIENCE

Saberwal, G
Bio-business in brief: A bit about technology transfer
Current Science, 99, 177-180 (2010)

Saberwal, G
Bio-business in brief: The debate over biosimilars
Current Science, 98, 1575-1578 (2010)

Saberwal, G
Bio-business in brief: The paradox of being a drug company
Current Science, 97, 623-625 (2009)

Devaguptapu, S, Mehdiratta, R and Saberwal, G
Bio-business in brief: The case of Cytokinetics Inc.
Current Science, 94, 1576-1581 (2008)

Mehdiratta, R,  Parida, D K and Saberwal, G
Bio-business in brief: The challenges of clinical trials
Current Science, 93, 1367-1375 (2007)

Mehdiratta, R and Saberwal, G
Bio-business in brief: Many a monoclonal.
Current Science, 93, 789-796 (2007)

Mehdiratta, R and Saberwal, G
Bio-business in brief: The case of conotoxins.
Current Science, 92, 39-45 (2007)

PERSPECTIVES AND OTHER ARTICLES

Saberwal, G
Caring for a severely disabled person.
Available at http://db.tt/bVuyIfN6

Soby, S., Kandasamy, M. and Saberwal, G
Work outsourced to Indian biotech and pharma companies is not yet significantly innovative.
Current Science (in press)

Kapoor, M. and Saberwal, G
The new crossroads
Biotech News, 5, 143-145 (2010).

Saberwal, G.
Drug development in India: What does the future look like?
Contemporary Perspectives: History and Sociology of South Asia, Ed. N Tyabji, 3, 293-309 (2009)

Saberwal, G
A long march
Biotech News, IV, 68-69 & 75 (2009)

Saberwal, G.  Biotechnology Incubation in India.  In Business incubation: Initiatives in India Ed. R. K. Lagu, brought out by NSTEDB, DST (2004)

FUNDING

We have received generous funding from the Wadhwani Foundation and the Institut Merieux to support our research and teaching.